Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05187351 · ClinicalTrials.gov registry record
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
A clinical trial of Percutaneous Coronary Intervention and Target Vessel Failure in Saphenous Vein Grafts, sponsored by Minneapolis Heart Institute Foundation.
- Active
- Registry status
- 99
- Enrollment target
- 2
- Study locations
NCT05187351: Active study of Percutaneous Coronary Intervention and Target Vessel Failure in Saphenous Vein Grafts, sponsored by Minneapolis Heart Institute Foundation.
NCT05187351 is a study of Percutaneous Coronary Intervention and Target Vessel Failure in Saphenous Vein Grafts that is active but no longer recruiting, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 99 participants, below the 5,217-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05187351, a study of Percutaneous Coronary Intervention and Target Vessel Failure in Saphenous Vein Grafts, is active but no longer recruiting, sponsored by Minneapolis Heart Institute Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- 99 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary study objective of the NASA registry is to evaluate the 12-month incidence of target vessel failure (TVF) in patients who present with saphenous vein graft (SVG) lesions and undergo percutaneous coronary intervention (PCI) of the corresponding native coronary artery.
Primary Outcome
Investigating the incidence of target vessel failure in patients with saphenous vein graft lesions who undergo PCI of the native coronary artery. or coronary bypass surgery, and tamponade requiring pericardiocentesis or surgery.
Conditions Studied
Interventions
- PROCEDURE Percutaneous coronary intervention of the native coronary artery with Synergy
Study Locations (2)
Michigan
- Henry Ford Health System - Detroit
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2021-11-21 |
| Est. Completion | 2030-01 |
What the registry record for NCT05187351 still lists
NCT05187351 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 5,217-participant average among 12 other Percutaneous Coronary Intervention trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Percutaneous Coronary Intervention appearing as the primary indexed condition, and to 1 intervention - of which Percutaneous coronary intervention of the native coronary artery with Synergy is the first listed.
NCT05187351 reports a single indexed study location in Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05187351 about?
NCT05187351 is a clinical study titled "Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions". The primary study objective of the NASA registry is to evaluate the 12-month incidence of target vessel failure (TVF) in patients who present with saphenous vein graft (SVG) lesions and undergo percutaneous coronary intervention (PCI) of the corresponding native coronary artery.
What is the current status of trial NCT05187351?
This trial is currently active not recruiting. The enrollment target is 99 participants. The study started on 2021-11-21. Estimated completion is 2030-01.
What conditions does trial NCT05187351 study?
This clinical trial studies the following conditions: Percutaneous Coronary Intervention, Target Vessel Failure in Saphenous Vein Grafts.
What interventions are being tested in trial NCT05187351?
The interventions under investigation include: Percutaneous coronary intervention of the native coronary artery with Synergy (PROCEDURE).
Who is sponsoring clinical trial NCT05187351?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05187351 being conducted?
This trial has 2 study locations across Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Percutaneous Coronary Intervention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05187351's enrollment target sits among peer trials
99 12th of 12 higher than 1 of 12 other Percutaneous Coronary Intervention trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Percutaneous Coronary Intervention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RECRUITING · Phase 4
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
ACTIVE NOT RECRUITING · NA
-
Precision PCI Registry
ACTIVE NOT RECRUITING
-
The xDAPT External Validation Study
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI